EE03383B1 - Kolesterooli biosünteesi inhibiitori ja kolesterooli absorptsiooni ß-laktaaminhibiitori kombinatsioon - Google Patents

Kolesterooli biosünteesi inhibiitori ja kolesterooli absorptsiooni ß-laktaaminhibiitori kombinatsioon

Info

Publication number
EE03383B1
EE03383B1 EE9400341A EE9400341A EE03383B1 EE 03383 B1 EE03383 B1 EE 03383B1 EE 9400341 A EE9400341 A EE 9400341A EE 9400341 A EE9400341 A EE 9400341A EE 03383 B1 EE03383 B1 EE 03383B1
Authority
EE
Estonia
Prior art keywords
inhibitor
cholesterol
pct
combination
lactam
Prior art date
Application number
EE9400341A
Other languages
English (en)
Estonian (et)
Other versions
EE9400341A (et
Inventor
R. Davis Harry
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of EE9400341A publication Critical patent/EE9400341A/xx
Publication of EE03383B1 publication Critical patent/EE03383B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EE9400341A 1992-12-23 1994-11-23 Kolesterooli biosünteesi inhibiitori ja kolesterooli absorptsiooni ß-laktaaminhibiitori kombinatsioon EE03383B1 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99548892A 1992-12-23 1992-12-23

Publications (2)

Publication Number Publication Date
EE9400341A EE9400341A (et) 1996-04-15
EE03383B1 true EE03383B1 (et) 2001-04-16

Family

ID=25541876

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9400341A EE03383B1 (et) 1992-12-23 1994-11-23 Kolesterooli biosünteesi inhibiitori ja kolesterooli absorptsiooni ß-laktaaminhibiitori kombinatsioon

Country Status (32)

Country Link
US (1) US5661145A (enExample)
EP (1) EP0675714B1 (enExample)
JP (1) JP3992728B2 (enExample)
KR (1) KR100306936B1 (enExample)
CN (1) CN1090479C (enExample)
AT (1) ATE175872T1 (enExample)
AU (1) AU680864B2 (enExample)
CA (1) CA2152351C (enExample)
CZ (1) CZ287125B6 (enExample)
DE (1) DE69323213T2 (enExample)
DK (1) DK0675714T3 (enExample)
EE (1) EE03383B1 (enExample)
ES (1) ES2128552T3 (enExample)
FI (1) FI952916L (enExample)
GR (1) GR3029405T3 (enExample)
HR (1) HRP931515B1 (enExample)
HU (1) HU221724B1 (enExample)
IL (1) IL108112A (enExample)
LT (1) LT3300B (enExample)
LV (1) LV10919B (enExample)
MX (1) MX9308053A (enExample)
MY (1) MY109538A (enExample)
NO (1) NO311325B1 (enExample)
NZ (1) NZ259790A (enExample)
PL (1) PL174128B1 (enExample)
SG (1) SG45147A1 (enExample)
SI (1) SI9300677A (enExample)
SK (1) SK281173B6 (enExample)
TW (1) TW319698B (enExample)
WO (1) WO1994014433A1 (enExample)
YU (1) YU49060B (enExample)
ZA (1) ZA939552B (enExample)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
EP0782451A1 (en) * 1994-09-20 1997-07-09 Pfizer Inc. Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
CN1217656C (zh) 1995-11-02 2005-09-07 沃尼尔·朗伯公司 用于调节脂浓度的方法和药物组合物
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
WO2000063703A1 (en) 1999-04-16 2000-10-26 Schering Corporation Use of azetidinone compounds
AU783457B2 (en) * 2000-04-05 2005-10-27 Toray Industries, Inc. Adsorbents for high mobility group proteins and column for purifying body fluid
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
US6584357B1 (en) * 2000-10-17 2003-06-24 Sony Corporation Method and system for forming an acoustic signal from neural timing difference data
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
RS20100015A (sr) 2001-01-26 2010-12-31 Schering Corporation Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
HU230435B1 (hu) 2001-01-26 2016-06-28 Merck Sharp & Dohme Corp Szubsztituált azetidinon vegyületek alkalmazása szitoszterinémia kezelésére
CN1915429B (zh) * 2001-01-26 2010-12-15 先灵公司 过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
US6627757B2 (en) 2001-03-28 2003-09-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
CA2460340C (en) * 2001-09-21 2011-02-15 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
ATE411018T1 (de) * 2001-09-21 2008-10-15 Schering Corp Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
US6984645B2 (en) 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
DE10227508A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
JP4654035B2 (ja) 2002-11-05 2011-03-16 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗菌剤
MXPA05004811A (es) 2002-11-06 2005-07-22 Schering Corp Inhibidores de absorcion de colesterol para el tratamiento de trastornos autoinmunes.
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
MXPA05009502A (es) * 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
EP1810971B1 (en) * 2003-03-07 2013-12-25 Merck Sharp & Dohme Corp. Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
MXPA05009501A (es) * 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
US20060089374A1 (en) * 2003-07-17 2006-04-27 Glenn Cornett Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
WO2005021039A1 (en) * 2003-08-29 2005-03-10 Cotherix, Inc. Combination of cicletanine and an oral antidiabetic and/or blood lipid-lowering agent for treating diabetes and metabolic syndrome
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2005062824A2 (en) * 2003-12-23 2005-07-14 Merck & Co., Inc. Anti-hypercholesterolemic compounds
WO2005061452A1 (en) 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
WO2005069900A2 (en) * 2004-01-16 2005-08-04 Merck & Co., Inc. Npc1l1 (npc3) and methods of identifying ligands thereof
AR049655A1 (es) * 2004-07-01 2006-08-23 Schering Corp Antagonistas de nk1
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
US20060046996A1 (en) * 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
US20060154959A1 (en) * 2005-01-13 2006-07-13 Navitas Pharma Combination therapies of cicletanine and carvedilol
JP2008514718A (ja) * 2004-09-29 2008-05-08 シェーリング コーポレイション 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7368458B2 (en) 2005-01-12 2008-05-06 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076568A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Thiazolopyridines as cannabinoid receptor modulators
US7314882B2 (en) 2005-01-12 2008-01-01 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
US20070141174A1 (en) * 2005-01-13 2007-06-21 Navitas Pharma, Inc. Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
US20060160850A1 (en) 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
ES2319461T3 (es) 2005-02-10 2009-05-07 Bristol-Myers Squibb Company Dihidroquinazolinonas como moduladores de 5ht.
US7572808B2 (en) 2005-06-17 2009-08-11 Bristol-Myers Squibb Company Triazolopyridine cannabinoid receptor 1 antagonists
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
ATE450526T1 (de) * 2005-06-20 2009-12-15 Schering Corp Als antagonisten von histamin h3 geeignete piperidinderivate
UY29607A1 (es) * 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
AR057380A1 (es) * 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
MY148538A (en) * 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
AR057383A1 (es) * 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
SA06270191B1 (ar) * 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
US20070105817A1 (en) * 2005-11-09 2007-05-10 Jim Page Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension
AU2006331770A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist/inverse agonist
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
EP1986489A2 (en) 2006-02-24 2008-11-05 Schering Corporation Npc1l1 orthologues
TW200811098A (en) * 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
CA2661404A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
US20080312241A1 (en) * 2007-01-03 2008-12-18 Gilead Sciences, Inc. Cicletanine and PKC inhibitors in the treatment of pulmonary and cardiac disorders
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
US20100092479A1 (en) * 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
CA2756786A1 (en) 2009-03-27 2010-09-30 Bristol-Myers Squibb Company Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
WO2014039411A1 (en) 2012-09-05 2014-03-13 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
EP2892897A1 (en) 2012-09-05 2015-07-15 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
PE20210644A1 (es) 2018-07-19 2021-03-23 Astrazeneca Ab METODOS DE TRATAMIENTO DE HFpEF EMPLEANDO DAPAGLIFLOZINA Y COMPOSICIONES QUE COMPRENDEN LA MISMA
JP2024522718A (ja) 2021-06-16 2024-06-21 セルジーン コーポレーション 神経変性疾患の治療のための、カルボン酸基を含むアゼチジニル化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US4983597A (en) * 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
US5085473A (en) * 1990-10-09 1992-02-04 Yuhe Yang Air actuated car curtain device
ATE158789T1 (de) 1991-07-23 1997-10-15 Schering Corp Substituierte beta-lactam-verbindungen als hypocholesterolemische mittel und verfahren zu deren herstellung
US9205972B2 (en) 2012-01-26 2015-12-08 Intralot S.A.—Integrated Lottery Systems and Services Methods and systems for dispensing

Also Published As

Publication number Publication date
FI952916A0 (fi) 1995-06-14
US5661145A (en) 1997-08-26
FI952916A7 (fi) 1995-06-14
EE9400341A (et) 1996-04-15
EP0675714A1 (en) 1995-10-11
MY109538A (en) 1997-02-28
DE69323213D1 (de) 1999-03-04
KR100306936B1 (ko) 2001-11-30
LV10919A (lv) 1995-12-20
YU49060B (sh) 2003-08-29
LTIP1514A (en) 1994-10-25
SK78395A3 (en) 1996-05-08
LV10919B (en) 1996-04-20
SK281173B6 (sk) 2000-12-11
ZA939552B (en) 1994-10-12
FI952916L (fi) 1995-06-14
CA2152351C (en) 2009-09-22
IL108112A0 (en) 1994-04-12
HUT72081A (en) 1996-03-28
HU9501854D0 (en) 1995-08-28
CZ287125B6 (en) 2000-09-13
YU80293A (sh) 1997-12-05
EP0675714B1 (en) 1999-01-20
CZ164395A3 (en) 1996-03-13
AU5872094A (en) 1994-07-19
JP3992728B2 (ja) 2007-10-17
WO1994014433A1 (en) 1994-07-07
NO311325B1 (no) 2001-11-19
PL174128B1 (pl) 1998-06-30
AU680864B2 (en) 1997-08-14
NZ259790A (en) 1997-02-24
CN1095591A (zh) 1994-11-30
NO952529L (no) 1995-06-23
MX9308053A (es) 1994-06-30
TW319698B (enExample) 1997-11-11
DK0675714T3 (da) 1999-09-13
HRP931515B1 (en) 2000-02-29
HRP931515A2 (en) 1996-12-31
ES2128552T3 (es) 1999-05-16
SG45147A1 (en) 1998-01-16
HU221724B1 (hu) 2002-12-28
JPH08505141A (ja) 1996-06-04
PL309636A1 (en) 1995-10-30
NO952529D0 (no) 1995-06-23
ATE175872T1 (de) 1999-02-15
DE69323213T2 (de) 1999-07-08
SI9300677A (en) 1994-09-30
IL108112A (en) 1999-11-30
LT3300B (en) 1995-06-26
CA2152351A1 (en) 1994-07-07
CN1090479C (zh) 2002-09-11
GR3029405T3 (en) 1999-05-28

Similar Documents

Publication Publication Date Title
EE03383B1 (et) Kolesterooli biosünteesi inhibiitori ja kolesterooli absorptsiooni ß-laktaaminhibiitori kombinatsioon
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
BR9804352A (pt) Composição e processo para controlar o crescimento microbiológico.
MY114803A (en) Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
AU2483000A (en) Treatment of asthma with mek inhibitors
DE69831937D1 (de) Bicyclische protein-farnesyl-transferase inhibitoren
ES2131185T3 (es) Arilalcanil-n-hidroxiureas y heteroalquilalcanil-n-hidroxiureas sustituidas que pueden inhibir la biosintesis de leucotrienos.
AP9701007A0 (en) Substituted azetidin-2-ones for treatment of atherosclerosis.
AU3451797A (en) Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter
BG100510A (en) Method of treating androgenic alopecia with 5-alpha reductase inhibitors
MD960168A (ro) Metodă şi compuşi pentru tratamentul infecţiilor virale
MX9709466A (es) Medicamento para inhibir el melanoma.
HUT73231A (en) Pharmaceutical compositions with 17-beta-monosubstituted-carbamoyl-4-aza-5-alpha-androst-1-en-3-ones for treatment of chronic prostatitis
DE69717277D1 (en) Imidazopyridine
DE69534761D1 (de) Zusammensetzungen zur behandlung und vorbeugung von atherosklerose
ES2099417T3 (es) Composiciones fungicidas.
AU5625194A (en) Rectal flunisolide compositions for treating inflammatory intestinal disorders
UA41376C2 (uk) ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЛІКУВАННЯ АНДРОГЕННОЇ АЛОПЕЦІЇ ІНГІБІТОРАМИ 5-<font face="Symbol">a</font>-РЕДУКТАЗИ

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20111123